Investor Quick Links
Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.
About Aspira Women's Health
Our Mission
Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Most Recent Press Releases
Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
May 16, 2024 08:00 ET AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner’s Healthcare Showcase taking place…
Aspira Women’s Health Reports First Quarter 2024 Financial Results
May 15, 2024 07:30 ET Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…